ARCH Venture Partners, a Chicago, IL-based venture capital firm, closed ARCH Venture Fund XIII, at more than $3 billion.
The vehicle will support the founding and growth of early-stage biotechnology companies. ARCH founds and invests in early-stage companies that prevent, detect and cure disease.
Read more on VCWire.tech, our new website dedicated to the tech venture capital industry.
FinSMEs
26/09/2024